A Phase 2, Randomized, Controlled, Observer-blinded Study, Conducted To Describe The Immunogenicity, Safety And Tolerability Of A Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent Rlp2086) When Administered To Healthy Toddlers Aged 12 To <18 Months Or 18 To <24 Months.

Trial Profile

A Phase 2, Randomized, Controlled, Observer-blinded Study, Conducted To Describe The Immunogenicity, Safety And Tolerability Of A Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent Rlp2086) When Administered To Healthy Toddlers Aged 12 To <18 Months Or 18 To <24 Months.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs PF 5212366 (Primary) ; Hepatitis A vaccine
  • Indications Meningococcal group B infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 04 Oct 2017 Planned End Date changed from 1 Feb 2021 to 22 Feb 2021.
    • 27 Jun 2017 Planned primary completion date changed from 11 Sep 2017 to 17 Aug 2017.
    • 05 Apr 2017 Planned primary completion date changed from 1 Aug 2017 to 10 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top